This retrospective cohort study was conducted using data from the National Health Insurance Research Database (NHIRD), a database covering 99% of Taiwan's population of 23 million beneficiaries. The database included all insurance claims data, such as outpatient visits, emergency, and hospitalization. Among them, one million subjects (Longitudinal Health Insurance Research Database) \[[@pone.0238242.ref017]--[@pone.0238242.ref019]\] were randomly sampled from the 23 million beneficiaries, providing data from 1999 to 2013. The sampled database was de-identified and this study was approved by the Institutional Review Board of Chung Shan Medical University Hospital (Approval number CS15134). All relevant data are within the manuscript.

Introduction {#sec001}
============

Tonsillectomy is one of the most frequently performed surgical interventions worldwide. However, studies have shown that the tonsils are important part of the immune system, playing special roles in pathogen detection and defense. The tonsils form a Waldeyer's ring around the apex of the respiratory and alimentary tracts, providing an early warning of airborne or ingested pathogens/antigens. The tonsils act as gatekeepers and can directly and indirectly resist pathogens by stimulating other immune responses \[[@pone.0238242.ref001], [@pone.0238242.ref002]\]. Previous studies have found a dramatic decline in pre-existing antigen-specific IgA antibodies in the nasopharynx after tonsillectomy \[[@pone.0238242.ref003]\], suggesting that the tonsils are critical for generating mucosal immunity. Furthermore, the tonsils are also considered to be a reservoir of T cells in addition to the thymus \[[@pone.0238242.ref004]\]. Changes in immune function after tonsillectomy have been reported, but the results remain controversial. Studies have examined the association between antecedent removal of tonsils and the risk of respiratory disorders \[[@pone.0238242.ref005]\], infectious diseases \[[@pone.0238242.ref005]\], asthma \[[@pone.0238242.ref005]\], premature acute myocardial infarction \[[@pone.0238242.ref006]\], autoimmune diseases \[[@pone.0238242.ref007]\], inflammatory bowel disease \[[@pone.0238242.ref008], [@pone.0238242.ref009]\], and cancers \[[@pone.0238242.ref010]\]. The absence of tonsils might have a lasting impact on human health.

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that is characterized by recurrent abdominal pain in association with a change in bowel habit, with diarrhea, constipation, or both \[[@pone.0238242.ref011]\]. IBS has a considerable negative impact on patients' quality of life and work productivity and is still a mysterious cause of significant distress and morbidity. Impairment of health-related quality of life in IBS patients has been shown to be comparable to, or possibly even more severe than, other serious chronic organic diseases like inflammatory bowel disease, diabetes, hypertension, and end-stage renal failure \[[@pone.0238242.ref012]\]. The pathophysiology of IBS is multifactorial, including changes in visceral hypersensitivity, intestinal motility, gut-brain interaction, mucosal immunity, and so on. However, many studies showed that alteration of the gut microbiome occurred in the majority of IBS patients \[[@pone.0238242.ref013]\]. One recent study showed that severity of IBS symptoms was associated with reduced diversity and richness of the intestinal microbiome \[[@pone.0238242.ref014]\]. There is also evidence implicating antecedent infections of bacteria, viruses, protozoa, and even fungi in the pathogenesis of IBS. This type of IBS is termed post-infectious IBS. To date, the causative factors of IBS remain incompletely understood.

The short-term complications of tonsillectomy are well -explored, whereas relatively little is known about the long-term complications. The absence of tonsils might cause undetectable pathogens to penetrate the alimentary tract, leading to post-infectious IBS \[[@pone.0238242.ref015]\] or small bowel bacterial overgrowth. It has been postulated that in susceptible populations, acute or recurrent infections increase intestinal permeability by weakening tight junctions \[[@pone.0238242.ref011]\]. Localized inflammation then develops, followed by subsequent immune activation and even gut dysbiosis \[[@pone.0238242.ref011], [@pone.0238242.ref016]\], which can lead to IBS. The aim of this study was to evaluate the risk of developing IBS after receiving tonsillectomy. We thus hypothesized that tonsillectomy could modify the risk of IBS. This hypothesis was tested by analyzing a nationwide population-based retrospective cohort from Taiwan's National Health Insurance Research Database (NHIRD).

Material and methods {#sec002}
====================

Data source {#sec003}
-----------

This retrospective cohort study was conducted using data from the National Health Insurance Research Database (NHIRD), a database covering 99% of Taiwan's population of 23 million beneficiaries. The database included all insurance claims data, such as outpatient visits, emergency, and hospitalization. Among them, one million subjects (Longitudinal Health Insurance Research Database) \[[@pone.0238242.ref017]--[@pone.0238242.ref019]\] were randomly sampled from the 23 million beneficiaries, providing data from 1999 to 2013. The sampled database was de-identified and this study was approved by the Institutional Review Board of Chung Shan Medical University Hospital (Approval number CS15134).

Study group and outcome measurement {#sec004}
-----------------------------------

The study population included patients with records of newly diagnosed chronic diseases of tonsils and adenoids (ICD-9-CM code 474) or peritonsillar abscess (ICD-9-CM code 475) from 2000 to 2010 for at least 3 outpatient visits or one inpatient admission within 2 years in order to ensure the accuracy of diagnosis. The tonsillectomy group included individuals with records of tonsillectomy procedure within 2 years of diagnosis of chronic diseases of tonsils and adenoids or peritonsillar abscess. The index date of this cohort was set as the date occurring two years after the first diagnosis date. The non-tonsillectomy group included patients without records of tonsillectomy procedure after diagnosis of chronic diseases of tonsils and adenoids or peritonsillar abscess. Individuals whose diagnosis of IBS (ICD-9-CM code 564.1) was prior to the index date were excluded. The outcome was defined as new-onset IBS diagnosis (ICD-9-CM code 564.1) during at least three outpatient visits or one hospital admission. The participants were followed up until the occurrence of IBS before the end of 2013, or withdrawal from the National Health Insurance system.

Covariates and matching {#sec005}
-----------------------

The baseline characteristics included age, gender, hypertension (ICD-9-CM 401--405), hyperlipidemia (ICD-9-CM 272.0--272.4), chronic liver disease (ICD-9-CM 571), chronic kidney disease (ICD-9-CM 585), diabetes (ICD-9-CM 250), chronic obstructive pulmonary disease (COPD) (ICD-9-CM 491, 492, 496), cancer (ICD-9-CM 140--208), coronary artery disease (ICD-9-CM 410--414), autoimmune disease (ICD-9-CM 710.0, 720.0, 714.0), gastrointestinal (GI) infectious disease (ICD-9-CM 001--009), anxiety (ICD-9-CM 300.0), and depression (ICD-9-CM 296.2, 296.3, 300.4 and 311). The aforementioned comorbidities were included in the analyses if they were noted one year before the index date for at least once hospitalization or three outpatient visits. In addition, usage of oral or injected corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and antibiotics for ≥30 days during the study period were also included in the analyses.

Then, propensity scores were matched by age, gender, hypertension, hyperlipidemia, chronic liver disease, chronic kidney disease, diabetes, chronic obstructive pulmonary disease, cancer, cardiovascular disease, autoimmune disease, corticosteroids, and index year to control for potential confounding factors. The propensity score was a probability estimated by logistic regression, with the binary variable being whether or not patients had received tonsillectomy, i.e., tonsillectomy vs. non-tonsillectomy groups. By matching propensity scores, the heterogeneity of baseline characteristics, and comorbidities between the two groups were balanced.

Statistical analysis {#sec006}
--------------------

The comparison of the tonsillectomy group and non-tonsillectomy group was defined as the absolute standardized differences (ASD). The ASD between the covariates of these two groups after propensity score matching were \<10%, which indicates a good balance between tonsillectomy and non-tonsillectomy cohorts. Kaplan-Meier analysis was used to calculate the cumulative incidence of IBS and the log-rank test was used to test the significance. Cox proportional hazard model was used to estimate the hazard ratio of IBS between the tonsillectomy group and non-tonsillectomy group. SPSS version 18.0 (SPSS Inc., Chicago, IL, USA) was used for the statistical analyses.

Results {#sec007}
=======

Basic demographic characteristics of the study subjects {#sec008}
-------------------------------------------------------

A total of 9,410 patients diagnosed with chronic disease of tonsils and adenoids or peritonsillar abscess were identified from the NHI database. Among them, 7,885 patients did not receive tonsillectomy, whereas 1,457 patients received tonsillectomy within two years. After excluding patients diagnosed with IBS before tonsillectomy, there were 6,985 non-tonsillectomy and 1,306 tonsillectomy patients. After propensity score matching, there were 2,600 patients in the non-tonsillectomy group and 1,300 patients in the tonsillectomy group ([Fig 1](#pone.0238242.g001){ref-type="fig"} and [Table 1](#pone.0238242.t001){ref-type="table"}).

![Flowchart of study.](pone.0238242.g001){#pone.0238242.g001}

10.1371/journal.pone.0238242.t001

###### Demographic characteristics of tonsillectomy group and non-tonsillectomy group.

![](pone.0238242.t001){#pone.0238242.t001g}

                           Before propensity score matching                         After propensity score matching                                             
  ------------------------ ---------------------------------- ------------- ------- --------------------------------- ----------- ------- ------ ------- ------ -------
                           n                                  \%            n       \%                                ASD         n       \%     n       \%     ASD
  Age                                                                       0.290                                                                0.067          
  \<20                     505                                38.7          2223    31.8                                          502     38.6   1004    38.6   
  20--50                   670                                51.3          3375    48.3                                          667     51.3   1281    49.3   
  ≧50                      131                                10.0          1387    19.9                                          131     10.1   315     12.1   
  Mean ± SD                26.9 ± 16.2                        32.2 ± 19.9   0.291   26.9 ± 16.2                       28 ± 17.3   0.052                         
  Gender                                                                                                              0.178                                     0.003
  Female                   513                                39.3          3357    48.1                                          513     39.5   1022    39.3   
  Male                     793                                60.7          3628    51.9                                          787     60.5   1578    60.7   
  Hypertension             69                                 5.3           574     8.2                               0.117       69      5.3    152     5.8    0.023
  Hyperlipidemia           43                                 3.3           240     3.4                               0.008       40      3.1    61      2.3    0.045
  Chronic liver disease    36                                 2.8           124     1.8                               0.066       33      2.5    63      2.4    0.007
  Chronic kidney disease   3                                  0.2           23      0.3                               0.019       3       0.2    6       0.2    0.000
  Diabetes                 34                                 2.6           255     3.7                               0.060       34      2.6    54      2.1    0.036
  COPD                     11                                 0.8           114     1.6                               0.071       10      0.8    16      0.6    0.019
  Cancer                   12                                 0.9           94      1.3                               0.040       12      0.9    16      0.6    0.035
  Cardiovascular disease   19                                 1.5           149     2.1                               0.051       19      1.5    26      1.0    0.042
  Autoimmune disease       4                                  0.3           29      0.4                               0.018       4       0.3    9       0.3    0.007
  GI infectious disease    12                                 0.9           90      1.3                               0.035       12      0.9    30      1.2    0.023
  GERD                     14                                 1.1           52      0.7                               0.035       14      1.1    19      0.7    0.037
  Anxiety                  31                                 2.4           125     1.8                               0.041       31      2.4    28      1.1    0.100
  Depression               25                                 1.9           89      1.3                               0.051       25      1.9    36      1.4    0.042
  Corticosteroids          203                                15.5          1247    17.9                              0.062       202     15.5   401     15.4   0.003
  NSAIDs                   871                                66.7          4818    69.0                              0.049       869     66.8   1666    64.1   0.058
  Antibiotics              789                                60.4          4343    62.2                              0.036       787     60.5   1477    56.8   0.076
  Opioids                  74                                 5.7           387     5.5                               0.005       73      5.6    95      3.7    0.093
  Index year                                                                                                          0.360                                     0.049
  2002                     135                                10.3          1224    17.5                                          135     10.4   270     10.4   
  2003                     156                                11.9          966     13.8                                          156     12.0   313     12.0   
  2004                     149                                11.4          921     13.2                                          149     11.5   303     11.7   
  2005                     111                                8.5           708     10.1                                          111     8.5    228     8.8    
  2006                     143                                10.9          590     8.4                                           143     11.0   293     11.3   
  2007                     113                                8.7           598     8.6                                           113     8.7    228     8.8    
  2008                     120                                9.2           482     6.9                                           119     9.2    226     8.7    
  2009                     107                                8.2           450     6.4                                           106     8.2    213     8.2    
  2010                     91                                 7.0           385     5.5                                           91      7.0    178     6.8    
  2011                     97                                 7.4           405     5.8                                           96      7.4    186     7.2    
  2012                     84                                 6.4           256     3.7                                           81      6.2    162     6.2    

ASD: absolute Standardized Differences. The ASD between the covariates of these two groups after propensity score matching were less than 0.1, which indicates a good balance between tonsillectomy and non-tonsillectomy cohorts.

COPD: Chronic obstructive pulmonary disease.

GERD: Gastroesophageal reflux disease.

Risk of IBS in tonsillectomy {#sec009}
----------------------------

A total of 59 cases of IBS were identified over 27,005 observed person-years, and 27 of these cases were associated with tonsillectomy. Cumulative probability of IBS was found to be significantly higher for patients with tonsillectomy over a 12-year period of follow-up (Log-rank test, p = 0.039) ([Fig 2](#pone.0238242.g002){ref-type="fig"}). The incidence density of IBS patients with tonsillectomy was higher than that among the non-tonsillectomy cohort (3.0 vs 1.8 per 1000 person-years). The Cox proportional hazard model revealed that patients with tonsillectomy had a significantly higher risk of IBS compared to patients without tonsillectomy (adjusted hazard ratio \[HR\]:1.84, 95% CI: 1.09--3.09) after adjusting for possible confounding variables. Patients with hypertension, chronic liver disease, or anxiety had a higher risk of IBS in crude HR, but the adjusted HR showed no significance (adjusted HR: 2.18, 95% CI: 0.90--5.31; adjusted HR 2.41, 95% CI: 0.87--6.73 and adjusted HR: 2.37, 95% CI: 0.61--9.22) ([Table 2](#pone.0238242.t002){ref-type="table"}). The subgroup analysis showed that there was a difference in the risk of IBS in tonsillectomy patients based on age 50 years or older vs. younger than 50 years (p-value for interaction = 0.214). Specifically, patients aged 50 years or older had a significantly higher risk of developing IBS (adjusted HR: 3.79, 95% CI: 1.35--10.64), whereas there was no significant increase in risk for patients aged between 20 and 50 years, and patients younger than 20 years ([Table 3](#pone.0238242.t003){ref-type="table"}). In addition, there was a marginally significantly higher adjusted HR of 1.98 (95% CI: 0.99--3.95) for developing IBS when the follow-up period was longer than 3 years ([Table 4](#pone.0238242.t004){ref-type="table"}).

![Kaplan--Meier curves of the cumulative probability of IBS in the study groups.](pone.0238242.g002){#pone.0238242.g002}

10.1371/journal.pone.0238242.t002

###### Multiple Cox proportional hazard regression for the estimation of adjusted hazard ratios for IBS.

![](pone.0238242.t002){#pone.0238242.t002g}

                           No. of IBS   Observed Person-Years   Incidence Density (Per 1000 Person-Years)   Crude HR   95% C.I.      Adjusted HR[^†^](#t002fn003){ref-type="table-fn"}   95% C.I.
  ------------------------ ------------ ----------------------- ------------------------------------------- ---------- ------------- --------------------------------------------------- -------------
  Group                                                                                                                                                                                  
      Non-Tonsillectomy    32           18064                   1.8                                         1                        1                                                   
      Tonsillectomy        27           8941                    3.0                                         1.71       1.02--2.85    1.84                                                1.09--3.09
  Age                                                                                                                                                                                    
      \<20                 11           11350                   1.0                                         1                        1                                                   
      20--50               33           12968                   2.5                                         2.60       1.31--5.14    2.54                                                1.27--5.09
      ≧50                  15           2687                    5.6                                         5.65       2.59--12.32   5.85                                                2.41--14.19
  Gender                                                                                                                                                                                 
      Female               23           10680                   2.2                                         1                        1                                                   
      Male                 36           16325                   2.2                                         1.03       0.61--1.73    1.04                                                0.61--1.8
  Hypertension             9            1280                    7.0                                         3.58       1.76--7.29    2.18                                                0.90--5.31
  Hyperlipidemia           1            511                     2.0                                         0.86       0.12--6.24    0.32                                                0.04--2.52
  Chronic liver disease    5            608                     8.2                                         3.91       1.56--9.77    2.41                                                0.87--6.73
  Diabetes                 2            457                     4.4                                         2.00       0.49--8.22    1.06                                                0.22--5.03
  COPD                     1            173                     5.8                                         2.71       0.38--19.59   1.57                                                0.19--12.85
  Cancer                   1            209                     4.8                                         2.33       0.32--16.80   1.04                                                0.13--8.22
  Cardiovascular disease   1            238                     4.2                                         1.93       0.27--13.91   0.70                                                0.09--5.84
  Autoimmune disease       1            75                      13.3                                        6.73       0.93--48.6    5.54                                                0.72--42.72
  GI infectious disease    1            328                     3.0                                         1.41       0.20--10.2    2.02                                                0.27--14.9
  Anxiety                  3            368                     8.1                                         3.85       1.21--12.32   2.37                                                0.61--9.22
  Depression               2            402                     5.0                                         2.31       0.56--9.46    1.10                                                0.22--5.53
  Corticosteroids          9            4885                    1.8                                         0.83       0.41--1.69    0.77                                                0.35--1.70
  NSAIDs                   32           19726                   1.6                                         0.44       0.26--0.74    0.41                                                0.22--0.75
  Antibiotics              31           17836                   1.7                                         0.58       0.35--0.97    0.74                                                0.40--1.37
  Opioids                  3            1178                    2.5                                         1.16       0.36--3.70    0.74                                                0.21--2.62

COPD: Chronic obstructive pulmonary disease.

IBS: Irritable bowel syndrome.

†Adjusted for age, gender, hypertension, hyperlipidemia, chronic liver disease, diabetes, COPD, cancer, cardiovascular disease, autoimmune disease, GI infectious disease, anxiety, depression, corticosteroids, NSAIDs, opioids, and antibiotics.

10.1371/journal.pone.0238242.t003

###### Sensitivity analysis of adjusted hazard ratios (95% CI) stratified by sex and age groups.

![](pone.0238242.t003){#pone.0238242.t003g}

                              Tonsillectomy   Non-Tonsillectomy                      
  --------------------------- --------------- ------------------- ------ ---- ------ -------------
  Age                                                                                
      \<20                    502             5                   1004   6    1.71   0.52--5.6
      20--50                  667             13                  1281   20   1.24   0.62--2.49
      ≥50                     131             9                   315    6    3.79   1.35--10.64
  p for interaction = 0.214                                                          
  Gender                                                                             
      Female                  513             11                  1022   12   1.84   0.81--4.16
      Male                    787             16                  1578   20   1.62   0.84--3.13
  p for interaction = 0.808                                                          

IBS: Irritable bowel syndrome.

10.1371/journal.pone.0238242.t004

###### Sensitivity analysis of adjusted hazard ratios (95% CI) stratified by follow-up period.

![](pone.0238242.t004){#pone.0238242.t004g}

                                                    Tonsillectomy   Non-Tonsillectomy   HR     95% C.I.          
  ------------------------------------------------- --------------- ------------------- ------ ---------- ------ ------------
  Follow-up duration                                                                                             
  ≤3 years[^a^](#t004fn001){ref-type="table-fn"}    1300            11                  2600   15         1.51   0.69--3.30
  \>3 years[^b^](#t004fn002){ref-type="table-fn"}   1104            16                  2216   17         1.98   0.99--3.95

a: Adjusted for age, gender, hypertension, hyperlipidemia, chronic liver disease, cardiovascular disease, autoimmune disease, and corticosteroids.

b: Adjusted for age, gender, hypertension, chronic liver disease, diabetes, COPD, cancer, and corticosteroids.

Discussion {#sec010}
==========

In this study, we found a 1.84-fold higher risk of IBS in tonsillectomy patients, and the risk was higher in patients aged ≥ 50 years (adjusted HR of 3.79, 95% CI, 1.35--10.64). Furthermore, there was a marginally significantly higher risk of developing IBS when follow-up was longer than 3 years after tonsillectomy. The association between tonsillectomy and IBS has been explored in one previous case-control study, and prior tonsillectomy was observed in 59.5% and 40.5% of subjects with and without IBS \[[@pone.0238242.ref015]\]. However, the design of the study might have allowed some information bias to exist and may not have controlled for possible confounding factors. To date and to the best of our knowledge, this is the first cohort study to use a nationwide longitudinal population-based dataset to identify an increased IBS risk among patients with prior tonsillectomy. These results indicate that physicians should be alert to the possibility of IBS among patients undergoing tonsillectomy.

We also found that patients diagnosed with hypertension (crude HR, 3.58; 95% CI, 1.76--7.29), chronic liver disease (crude HR, 3.91; 95% CI, 1.56--9.77), or anxiety (crude HR, 3.85; 95% CI, 1.21--12.32) had greater risk of developing IBS. Moreover, patients with autoimmune disease appeared to be marginally related to subsequent IBS in our study. After adjusting for confounders, the adjusted HR of IBS in patients with autoimmune disease was 5.54(95% CI: 0.72--42.72) compared to those without this comorbidity, but this was not statistically significant. There may have been insufficient statistical power to detect significant differences due to the low incidence of autoimmune diseases in our patient population. Although a systematic review including 404 children conducted by Altwairqi et al. concluded that tonsillectomy had no negative impact on both cellular and humoral immunity in children \[[@pone.0238242.ref020]\], the effect of tonsillectomy on the immunity of adults and the elderly remained unclear. We found that patients aged 50 years or older who underwent tonsillectomy had a 3.79-fold higher risk of IBS. Aging-related immune dysregulation, leading to a chronic inflammatory state and aging-related dysbiosis might be the causes. We suspected that tonsillectomy may worsen pre-existing dysbiosis and immune dysregulation in elder patients and thus increase the risk of IBS.

The pathophysiology underlying the relationship between tonsillectomy and subsequent IBS remains uncertain. Klem et al. reported a meta-analysis of 45 studies that found the pooled risk of developing IBS was 4.2-fold higher in persons who had infectious enteritis in the past year compared with people without infectious enteritis \[[@pone.0238242.ref021]\]. We speculate that tonsils are important guardians for priming the immune system to pathogens. Tonsils area is the first major mucosa-associated immune barrier that foreign microorganisms have to confront to enter the alimentary tract. The removal of tonsils may allow pathogens to successfully enter the intestine without being detected, altering intestinal flora by influencing bacterial colonization or invasion of the alimentary tracts, leading to post-infectious IBS or even dysbiosis. Andreu-Ballester JC et al. have reported that GALTectomy (such as tonsillectomy and appendectomy) could significantly reduce levels of secretory IgA \[[@pone.0238242.ref003]\], which was the crucial mucosa-associated antibody against infections. This reduction in patients undergoing tonsillectomy even lasted for more than 20 years in that study \[[@pone.0238242.ref003]\]. The change of immune defense function may also contribute to the alteration of gut flora in IBS development. Interestingly, we found a higher risk of developing IBS when follow-up was longer than 3 years after tonsillectomy. Our observation implied that it may take a while after tonsillectomy to develop IBS, and repetitive pathogens exposure or altered gut flora over time after tonsillectomy might be the possible explanations. Many studies have demonstrated that dysbiosis of the intestinal microbiome plays important roles in the pathogenesis of IBS \[[@pone.0238242.ref022], [@pone.0238242.ref023]\]. A reproducible finding in IBS patients is a decrease in bacterial diversity and an increase in the temporal instability of the intestinal microbiota \[[@pone.0238242.ref024]\]. Moreover, a healthy immunity is also an important surveillance system, which helps to control and keep wide variety of microorganisms in the intestinal microbiota in balance \[[@pone.0238242.ref025]\]. The tonsils are a part of the immune system and comprised mucosa-associated lymphoid tissues that have been reported to have resident CD34+ cells, which contribute to differentiation of several immune cells, including T cells \[[@pone.0238242.ref026]\]. The association between tonsillectomy and the development of IBS seems immunologically reasonable. Recent research have indicated that CD4+FOXP3+ regulatory T cells (Treg) constitute an important T cell compartment in palatine and lingual tonsils \[[@pone.0238242.ref027]\] and CD4+CD25+ Treg cells are implicated to play a pivotal role in suppressing intestinal inflammation \[[@pone.0238242.ref028]\]. It is increasingly clear that low-grade inflammation of gut has been recognized as a key factor in pathophysiology of IBS \[[@pone.0238242.ref029], [@pone.0238242.ref030]\]. Tonsillectomy involving Treg cells depletion in the tonsils might play a role in the development of IBS. Intriguingly, tonsillectomy has been reported to be associated with a higher risk of Behcet's disease and Crohn's disease \[[@pone.0238242.ref009]\]. These associations might reinforce the proposal that tonsillectomy plays a more important role than was believed in altering gut immunity. Surprisingly, human tonsils were previously proved to be a niche for extrathymic T cell development, thereby contributing to the T cell repertoire, which primarily depends on a functional thymus \[[@pone.0238242.ref031]\]. Since aging causes a dramatic loss of the thymus, leading to shrinkage in size of the naive T cell repertoire pool, an aging immune system tends to elicit nonspecific inflammation \[[@pone.0238242.ref032]\]. Tonsils appear to help compensate for this loss by actively maintaining the pool size of naive T cells in older individuals, and by helping to differentiate between commensal and pathogenic bacteria in the alimentary tract to prevent unnecessary immune responses. Therefore, we speculated that tonsillectomy in older patients, would show an especially high correlation with IBS development, compared with their younger counterparts in the present study. Consistent with our finding that there was no significant correlation of tonsillectomy with IBS in younger patients, a recent study found evidences supporting the idea that tonsillectomy has a limited effect on T cell-mediated adaptive immunity in children, indicating that having a functional thymus is rather important in young individuals undergoing this procedure \[[@pone.0238242.ref020]\]. Nevertheless, the mechanism responsible for tonsil-mediated immune dysfunction, which accelerates IBS development, requires further in-depth study.

The major strengths of this study were the large sample size and the relatively long duration of follow-up, in which a complete history of the medical services used was available for all cases and controls. Therefore, there was minimal selection, information, and recall bias, which made testing our hypothesis feasible. Furthermore, we used strict exclusion criteria and propensity score matching to control for potential confounders. Nonetheless, there were several limitations that should be noted. Firstly, the NHIRD does not disclose information regarding the patients' diet, socioeconomic status, family history, early adverse life events, personal lifestyle, psychological factors, body weight index, and inflammatory biomarkers, which may be associated risk factors for development of IBS. We used comorbidity variables such as COPD, cardiovascular disease, diabetes and hyperlipidemia as proxy variables to reflect the effects of smoking, dietary preferences, and sociodemographic status. Although we adjusted for various comorbidities and matched propensity scores, these unmeasured confounding factors might have biased our results. Secondly, the diagnoses of chronic disease of tonsils and adenoids, tonsillectomy, and comorbidities were entirely dependent on the ICD-9 codes in the administrative dataset. Therefore, validation of the accuracy of diagnoses could not be verified by personal review of medical records and may have resulted in misclassification. It is worth noting that these misclassifications are more likely to be random, and the associations are often underestimated rather than overestimated. While there is no confirmatory test for IBS, the diagnostic code based on the Rome criteria for IBS are widely used in Taiwan. Most clinicians in Taiwan used the Rome III criteria after 2006 and the Rome II criteria before 2006 for diagnosis of IBS. However, clinical judgment may differ among physicians, so diagnoses may have varied, which could have affected the validity of these diagnoses. However, Taiwan's NHI administration has established an ad hoc committee to monitor the accuracy of claims data to prevent violations. In addition, we only selected subjects that were repeatedly coded to improve the accuracy and validity of the diagnosis. Thirdly, due to the potential for residual confounding inherent in database research, the results should be interpreted with caution. Randomized control trials that are conducted to determine the effect of tonsillectomy and subsequent IBS are laborious and resource intensive. Such studies are difficult to conduct due to ethical issues involved in randomizing patients to undergo tonsillectomy to observe adverse outcomes. Nevertheless, we employed strict exclusion criteria and propensity score matching to control for potential confounders in order to emulate the advantages of a randomized clinical trial. Finally, the majority of the patients were Taiwanese and thus our findings may not be generalizable to other ethnic groups. Clinical studies that include patients from other countries and with different ethnicities should be conducted to confirm our result.

There is growing evidence showing that non-surgical management may be an effective and safe treatment for chronic/recurrent acute tonsillitis in children and adults \[[@pone.0238242.ref033], [@pone.0238242.ref034]\]. Our research supports evidence of an association between prior tonsillectomy and subsequent risk of IBS. Hence, the potential "benefit" of tonsillectomy must be weighed judiciously after considering the personal risk-benefit profile. Furthermore, patients undergoing tonsillectomy should be appropriately monitored for symptoms of IBS.

Conclusion {#sec011}
==========

Tonsillectomy was associated with a higher risk of developing irritable bowel syndrome in this nationwide, population-based cohort study. Further comprehensive basic and clinical research is warranted to elucidate the mechanisms underlying these associations.

This manuscript was edited by Wallace Academic Editing.

10.1371/journal.pone.0238242.r001
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Responses to the Additional Editor Comments:

This is an interesting epidemiological association study between tonsillectomy & IBS prevalence. As both reviewers have alluded to - please provide information about history of past GI infection or the use of antibiotics in the cohort studied. This should be included in the multi-variate analysis as well.

Response:

Many thanks you for your comments, we have done and enrolled history of past GI infections and antibiotics usage in the cohort study for multi-variate analysis as well. After multi-variate analysis and adjustment for patients' age, gender, comorbidities, and medications, patients who underwent tonsillectomy had a 1.84-fold risk of developing IBS compared to those without tonsillectomy (adjusted hazard ratio \[HR\]:1.84; 95% CI, 1.09-3.09).

The adjusted HR of developing IBS did not decrease even after adjusting for GI infectious disease, anxiety, depression, analgesics and antibiotics (according to the suggestions of reviewers' comments).

Dear editor, your comments help us to promote quality of this manuscript and we appreciate your kind suggestions.

Responses to the Reviewers' Comments:

Manuscript ID: PONE-D-20-01867

Manuscript title: Impact of tonsillectomy on irritable bowel syndrome: A nationwide population-based cohort study

Journal: PLOS ONE

Reviewer(s)\' Comments to Author:

Reviewer \#1: This is an interesting article suggesting that having a tonsillectomy is a risk factor for IBS. The authors do a very good job describing the trial and the data. It is very well written and clear. I was wondering if the authors examined post-infectious IBS. Food poisoning is a common cause of IBS. Perhaps the tonsils are important guardians for priming the immune system to pathogens. Could these two factors be linked. Their database could be used to show this.

Response:

Thank you for your comments. Gastrointestinal (GI) infections and food poisoning were worth exploring. We further enrolled gastrointestinal (GI) infectious disease (ICD-9-CM 001-009), anxiety (ICD-9-CM 300.0), and depression (ICD-9-CM 296.2, 296.3, 300.4 and 311). The aforementioned comorbidities were included in the analyses if they were noted one year before the index date for at least once hospitalization or three outpatient visits. In addition, usage of oral or injected corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and antibiotics for ≥30 days during the study period were also included and adjusted in the Cox proportional hazard model analyses. (Anxiety, depression, analgesics such as NSAIDs or opioids, antibiotics usage were suggested to examine according to reviewer\#2 comments)

However, there was no food poisoning event in both cohorts using claimed code: ICD-9-CM external causes of injury codes (E-Codes), which include "unintentional poisoning, such as by foodstuffs (E865) for food poisoning. Therefore, it is not applicable for multi-variate analysis.

p.s.

The official NHI database employ the ICD-9-CM coding system in Taiwan, so we selected cases by ICD-9-CM external causes of injury codes (E-Codes), which include "unintentional poisoning, such as by foodstuffs (E865) for food poisoning. However, there was no food poisoning event in both cohorts using claimed code: accidental poisoning from unspecified foodstuff (E865). Therefore, it is not applicable for multi-variate analysis. Besides, the code, ICD-9-CM 005 (other bacterial food poisoning), have been enrolled in the cases of GI infections for further multi-variate analysis.

GI infections (ICD-9-CM 001-009) were analyzed. The codes include: 001 (cholera), 002 (typhoid and paratyphoid fever), 003 (salmonellosis), 004 (shigellosis), 005 (other bacterial food poisoning), 006 (amoebiasis), 007 (other protozoan intestinal diseases), 008 (intestinal infections due to other organisms including 00861 enteritis due to rotavirus), 009 (ill-defined intestinal infections)

We revised the paragraph in method section:

"The baseline characteristics included age, gender, hypertension (ICD-9-CM 401-405), hyperlipidemia (ICD-9-CM 272.0-272.4), chronic liver disease (ICD-9-CM 571), chronic kidney disease (ICD-9-CM 585), diabetes (ICD-9-CM 250), chronic obstructive pulmonary disease (COPD) (ICD-9-CM 491, 492, 496), cancer (ICD-9-CM 140-208), coronary artery disease (ICD-9-CM 410-414), autoimmune disease (ICD-9-CM 710.0, 720.0, 714.0), gastrointestinal (GI) infectious disease (ICD-9-CM 001-009), anxiety (ICD-9-CM 300.0), and depression (ICD-9-CM 296.2, 296.3, 300.4 and 311). The aforementioned comorbidities were included in the analyses if they were noted one year before the index date for at least once hospitalization or three outpatient visits. In addition, usage of oral or injected corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and antibiotics for ≥30 days during the study period were also included in the analyses."

After multi-variate analysis and adjustment for patients' age, gender, comorbidities, and medications, patients who underwent tonsillectomy had a 1.84-fold risk of developing IBS compared to those without tonsillectomy (adjusted hazard ratio \[HR\]:1.84; 95% CI, 1.09-3.09).

In addition, we further analyzed GI infections (ICD-9-CM 001-009) in observational periods since index date. The results were not significantly different between the tonsillectomy and non-tonsillectomy cohorts. GI infections in observational periods did not show significant influence on IBS risk in our study.

We also add the sentence as your suggestion in 3rd paragraph of discussion section:

"...........We speculate that tonsils are important guardians for priming the immune system to pathogens...................."

Besides, we have added revised figure 1, table 1 and table 2 in the revised manuscript.

We thank you again for your best comments. Dear reviewer, your comments helps us to promote quality of this manuscript and we appreciate your kind suggestions.

Reviewer \#2: Thank you to the authors for looking at an interesting part of IBS epidemiology and natural history.

1\. Firstly, what the authors describe is an association, and I would be hesitant to write in their conclusions that patients with tonsillectomy have a significantly higher risk of developing IBS, especially since there are so many factors that are not controlled.

Under covariates and matching paragraph, how did the authors choose the variables to do propensity matching. These are not the usual variables that we look at when we analyse a functional GI cohort. Other more important variables to look at include mental health issues, or GERD or even early adverse life events. I appreciate these are

hard data to get from such databases, but therefore, the conclusions cannot be made without controlling for these things.

Response:

Many thanks for your comments, we revised the conclusion carefully as below:

"Tonsillectomy was associated with a higher risk of developing irritable bowel syndrome in this nationwide, population-based cohort study. ............"

We considered the baseline comorbidities based on the recently published papers (as references below) using the Longitudinal Health Insurance Research Database of the National Health Insurance Research Database in Taiwan to explore the same outcome, 'irritable bowel syndrome'. Baseline comorbidities used as relevant variables were listed in these references. In addition to the baseline comorbidities used in our research, other more important variables for developing IBS as reviewers' suggestion were worth exploring, such as mental health issues including anxiety and depression, GERD or even early adverse life events. However, no IBS event was found in patients with the comorbidity of GERD in both cohorts (14 in tonsillectomy and 19 in non-tonsillectomy cohorts with GERD comorbidity after propensity scoring matching, as shown in revised table 1; however, no IBS event found in the study period in both cohorts). Therefore, it is not applicable for multi-variate analysis. Early adverse life events were hard data to get from our database, it is an inherent limitation of population-based datasets such as the NHIRD. We have added this point as a limitation in discussion section.

We further enrolled gastrointestinal (GI) infectious disease (ICD-9-CM 001-009), anxiety (ICD-9-CM 300.0), and depression (ICD-9-CM 296.2, 296.3, 300.4 and 311). The aforementioned comorbidities were included in the analyses if they were noted one year before the index date for at least once hospitalization or three outpatient visits. In addition, usage of oral or injected corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and antibiotics for ≥30 days during the study period were also included and adjusted in the Cox proportional hazard model analyses. (GI infectious disease was suggested to explore according to reviewer\#1 comments)

After multi-variate analysis and adjustment for patients' age, gender, comorbidities, and medications, patients who underwent tonsillectomy had a 1.84-fold risk of developing IBS compared to those without tonsillectomy (adjusted hazard ratio \[HR\]:1.84; 95% CI, 1.09-3.09).

References:

Lei WY, Chang CY, Wu JH, Lin FH, Hsu Chen C, Chang CF, et al. An Initial Attack of Urinary Stone Disease Is Associated with an Increased Risk of Developing New-Onset Irritable Bowel Syndrome: Nationwide Population-Based Study. PLoS One. 2016;11(6):e0157701. doi: 10.1371/journal.pone.0157701.

Shen TC, Lin CL, Wei CC, Chen CH, Tu CY, Hsia TC, et al. Bidirectional Association between Asthma and Irritable Bowel Syndrome: Two Population-Based Retrospective Cohort Studies. PLoS One. 2016;11(4):e0153911. doi: 10.1371/journal.pone.0153911.

Liang CM, Hsu CH, Chung CH, Chen CY, Wang LY, Hsu SD, et al. Risk for Irritable Bowel Syndrome in Patients with Helicobacter Pylori Infection: A Nationwide Population-Based Study Cohort Study in Taiwan. Int J Environ Res Public Health. 2020;17(10). doi: 10.3390/ijerph17103737.

Yang CY, Wu MC, Lin MC, Wei JC. Risk of irritable bowel syndrome in patients who underwent appendectomy: A nationwide population-based cohort study. EClinicalMedicine. 2020;23:100383. doi: 10.1016/j.eclinm.2020.100383.

We have revised the paragraph in method section:

"The baseline characteristics included age, gender, hypertension (ICD-9-CM 401-405), hyperlipidemia (ICD-9-CM 272.0-272.4), chronic liver disease (ICD-9-CM 571), chronic kidney disease (ICD-9-CM 585), diabetes (ICD-9-CM 250), chronic obstructive pulmonary disease (COPD) (ICD-9-CM 491, 492, 496), cancer (ICD-9-CM 140-208), coronary artery disease (ICD-9-CM 410-414), autoimmune disease (ICD-9-CM 710.0, 720.0, 714.0), gastrointestinal (GI) infectious disease (ICD-9-CM 001-009), anxiety (ICD-9-CM 300.0), and depression (ICD-9-CM 296.2, 296.3, 300.4 and 311). The aforementioned comorbidities were included in the analyses if they were noted one year before the index date for at least once hospitalization or three outpatient visits. In addition, usage of oral or injected corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and antibiotics for ≥30 days during the study period were also included in the analyses."

And, we have made corresponding changes to the results, discussion section, and also in table 1-2.

In 2nd paragraph of results section:

.......................The Cox proportional hazard model revealed that patients with tonsillectomy had a significantly higher risk of IBS compared to patients without tonsillectomy (adjusted hazard ratio \[HR\]:1.84, 95% CI: 1.09-3.09) after adjusting for possible confounding variables. Patients with hypertension, chronic liver disease, or anxiety had a higher risk of IBS in crude HR, but the adjusted HR showed no significance (adjusted HR: 2.18, 95% CI: 0.90-5.31; adjusted HR 2.41, 95% CI: 0.87-6.73 and adjusted HR: 2.37, 95% CI: 0.61-9.22) (Table 2). ............

In 2nd paragraph of discussion section:

We also found that patients diagnosed with hypertension (crude HR, 3.58; 95% CI, 1.76-7.29), or chronic liver disease (crude HR, 3.91; 95% CI, 1.56-9.77), or anxiety (crude HR, 3.85; 95% CI, 1.21-12.32) had greater risk of developing IBS. .............

We have also revised the 4rd paragraph of discussion section and added 'early adverse life events' as a limitation as below:

..................Firstly, the NHIRD does not disclose information regarding the patients' diet, socioeconomic status, family history, early adverse life events, personal lifestyle, psychological factors, body weight index, and inflammatory biomarkers, which may be associated risk factors for development of IBS.

2\. For Table 1, there is a need to elaborate in the column under ASD, what each number means for the general reader who may not be sure.

Response:

Thank you for your suggestion. We add a footnote about ASD in table 1.

ASD: absolute Standardized Differences. The ASD between the covariates of these two groups after propensity score matching were less than 0.1, which indicates a good balance between tonsillectomy and non-tonsillectomy cohorts.

3\. The authors found an interesting result of older patients and also those on longer follow up developing IBS. Perhaps they should shed light based on their literature search on possible explanations for these phenomenons. For their explanations on the reason tonsillectomies predispose patients to IBS, I feel it is overly simplistic to think

that tonsils can modulate gut microbiota since the gut immune system distal to the tonsils are complex and more directly involved in controlling pathogens.

Response:

Thank you for your suggestions. For explanations on the reason tonsillectomies predispose patients to IBS, we have revised the discussion section based on literature search on possible explanations for these phenomenons as below. We have focused on how tonsillectomy can alter immunity (such as by reducing secretory IgA and involving Treg cells depletion) and further strengthened the description of tonsils as important guardians for priming the immune system to pathogens, and added new references to shed light the possible mechanisms underlying these associations.

In 3rd paragraph of discussion section:

".....................We speculate that tonsils are important guardians for priming the immune system to pathogens. Tonsils area is the first major mucosa-associated immune barrier that foreign microorganisms have to confront to enter the alimentary tract. The removal of tonsils may allow pathogens to successfully enter the intestine without being detected, altering intestinal flora by influencing bacterial colonization or invasion of the alimentary tracts, leading to post-infectious IBS or even dysbiosis. Andreu-Ballester JC et al. have reported that GALTectomy (such as tonsillectomy and appendectomy) could significantly reduce levels of secretory IgA \[3\], which was the crucial mucosa-associated antibody against infections. This reduction in patients undergoing tonsillectomy even lasted for more than 20 years in that study \[3\]. The change of immune defense function may also contribute to the alteration of gut flora in IBS development. Interestingly, we found a higher risk of developing IBS when follow-up was longer than 3 years after tonsillectomy. Our observation implied that it may take a while after tonsillectomy to develop IBS, and repetitive pathogens exposure or altered gut flora over time after tonsillectomy might be the possible explanations. Many studies have demonstrated that dysbiosis of the intestinal microbiome plays important roles in the pathogenesis of IBS \[22, 23\]. A reproducible finding in IBS patients is a decrease in bacterial diversity and an increase in the temporal instability of the intestinal microbiota \[24\]. Moreover, a healthy immunity is also an important surveillance system, which helps to control and keep wide variety of microorganisms in the intestinal microbiota in balance \[25\]. The tonsils are a part of the immune system and comprised mucosa-associated lymphoid tissues that have been reported to have resident CD34+ cells, which contribute to differentiation of several immune cells, including T cells \[26\]. The association between tonsillectomy and the development of IBS seems immunologically reasonable. Recent research have indicated that CD4+FOXP3+ regulatory T cells (Treg) constitute an important T cell compartment in palatine and lingual tonsils \[27\] and CD4+CD25+ Treg cells are implicated to play a pivotal role in suppressing intestinal inflammation \[28\]. It is increasingly clear that low-grade inflammation of gut has been recognized as a key factor in pathophysiology of IBS \[29, 30\]. Tonsillectomy involving Treg cells depletion in the tonsils might play a role in the development of IBS. Intriguingly, tonsillectomy has been reported to be associated with a higher risk of Behcet's disease and Crohn's disease \[9\]. These associations might reinforce the proposal that tonsillectomy plays a more important role than was believed in altering gut immunity. .................................................................................................................................................................................Nevertheless, the mechanism responsible for tonsil-mediated immune dysfunction, which accelerates IBS development, requires further in-depth study."

We have added references in discussion section:

3\. Andreu-Ballester JC, Perez-Griera J, Ballester F, Colomer-Rubio E, Ortiz-Tarin I, Penarroja Otero C. Secretory immunoglobulin A (sIgA) deficiency in serum of patients with GALTectomy (appendectomy and tonsillectomy). Clin Immunol. 2007;123(3): 289-297. doi: 10.1016/j.clim.2007.02.004.

27\. Palomares O, Rückert B, Jartti T, Kücüksezer UC, Puhakka T, Gomez E, et al. Induction and maintenance of allergen-specific FOXP3+ Treg cells in human tonsils as potential first-line organs of oral tolerance. J Allergy Clin Immunol. 2012;129(2):510-20, 20.e1-9. doi: 10.1016/j.jaci.2011.09.031.

28\. Makita S, Kanai T, Nemoto Y, Totsuka T, Okamoto R, Tsuchiya K, et al. Intestinal lamina propria retaining CD4+CD25+ regulatory T cells is a suppressive site of intestinal inflammation. J Immunol. 2007;178(8):4937-46. doi: 10.4049/jimmunol.178.8.4937.

29\. Sinagra E, Pompei G, Tomasello G, Cappello F, Morreale GC, Amvrosiadis G, et al. Inflammation in irritable bowel syndrome: Myth or new treatment target? World J Gastroenterol. 2016;22(7):2242-55. doi: 10.3748/wjg.v22.i7.2242.

30\. Akiho H, Ihara E, Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol. 2010;1(3):97-105. doi: 10.4291/wjgp.v1.i3.97.

We have mentioned in our discussion section regarding older patients would show a higher correlation with IBS development:

....................................Surprisingly, human tonsils were previously proved to be a niche for extrathymic T cell development, thereby contributing to the T cell repertoire, which primarily depends on a functional thymus \[31\]. Since aging causes a dramatic loss of the thymus, leading to shrinkage in size of the naive T cell repertoire pool, an aging immune system tends to elicit nonspecific inflammation \[32\]. Tonsils appear to help compensate for this loss by actively maintaining the pool size of naive T cells in older individuals, and by helping to differentiate between commensal and pathogenic bacteria in the alimentary tract to prevent unnecessary immune responses. Therefore, we speculated that tonsillectomy in older patients, would show an especially high correlation with IBS development, compared with their younger counterparts in the present study.................................................................

We also added the description in 2nd paragraph of discussion section regarding the elderly who underwent tonsillectomy had a higher risk of IBS.

"................Although a systematic review including 404 children conducted by Altwairqi et al. concluded that tonsillectomy had no negative impact on both cellular and humoral immunity in children \[20\], the effect of tonsillectomy on the immunity of adults and the elderly remained unclear. We found that patients aged 50 years or older who underwent tonsillectomy had a 3.79-fold higher risk of IBS. Aging-related immune dysregulation, leading to a chronic inflammatory state and aging-related dysbiosis might be the causes. We suspected that tonsillectomy may worsen pre-existing dysbiosis and immune dysregulation in elder patients and thus increase the risk of IBS."

4\. Are there other factors such as antibiotic use or analgesics used, that the

authors feel can mediate this association?

Response:

Thank you for your comments. Usage of analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and antibiotics for ≥30 days during the study period were also included in the multi-variate analyses. After multi-variate analysis and adjustment for patients' age, gender, comorbidities, and medications, patients who underwent tonsillectomy had a 1.84-fold risk of developing IBS compared to those without tonsillectomy (adjusted hazard ratio \[HR\]:1.84; 95% CI, 1.09-3.09).

The adjusted HR of developing IBS did not decrease even after adjusting for analgesics and antibiotics.

Dear reviewer, I greatly appreciate your time and your kind comments again; your comments reinforced our manuscript and we did our best to respond to your comments carefully.
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